Zheleva, A. (Angelina)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
3 results
Search Results
Now showing 1 - 3 of 3
- Modulating T Cell Responses by Targeting CD3(2023) Menon, A.P. (Ashwathi Puravankara); Nonatelli, F. (Francesca); Pastor, F. (Fernando); Moreno, B. (Beatriz); Villanueva-Ruiz, M.E. (María Elena); Meraviglia-Crivelli, D. (Daniel); van-Santen, H.M. (Hisse M.); Barainka, M. (Martin); Zheleva, A. (Angelina)Simple Summary CD3 complex provides the first signal sensed by the TCR of the lymphocyte to trigger its activation. Thus, it becomes a very attractive receptor to determine the fate of the immune response in different contexts from tolerance induction to immune activation. We discuss CD3-TCR complex assembly and the current and emerging approaches to harvest CD3 activity for immunotherapy. Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB. Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the first signal that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation. While the mechanisms through which antigen sensing and signal transduction occur in the CD3-TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3-TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3-TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3-TCR function for potentiating cancer immunotherapy.
- Therapeutic strategies to enhance tumor antigenicity: making the tumor detectable by the immune system(2022) Pastor, F. (Fernando); Moreno, B. (Beatriz); Villanueva-Ruiz, M.E. (María Elena); Meraviglia-Crivelli, D. (Daniel); Barainka, M. (Martin); Zheleva, A. (Angelina)Cancer immunotherapy has revolutionized the oncology field, but many patients still do not respond to current immunotherapy approaches. One of the main challenges in broadening the range of responses to this type of treatment is the limited source of tumor neoantigens. T cells constitute a main line of defense against cancer, and the decisive step to trigger their activation is mediated by antigen recognition. Antigens allow the immune system to differentiate between self and foreign, which constitutes a critical step in recognition of cancer cells and the consequent development or control of the malignancy. One of the keystones to achieving a successful antitumor response is the presence of potent tumor antigens, known as neoantigens. However, tumors develop strategies to evade the immune system and resist current immunotherapies, and many tumors present a low tumor mutation burden limiting the presence of tumor antigenicity. Therefore, new approaches must be taken into consideration to overcome these shortcomings. The possibility of making tumors more antigenic represents a promising front to further improve the success of immunotherapy in cancer. Throughout this review, we explored different state-of-the-art tools to induce the presentation of new tumor antigens by intervening at protein, mRNA or genomic levels in malignant cells.
- IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction(2022) Menon, A.P. (Ashwathi Puravankara); Pastor, F. (Fernando); Moreno, B. (Beatriz); Villanueva-Ruiz, M.E. (María Elena); Meraviglia-Crivelli, D. (Daniel); Villalba-Esparza, M. (María); Cebollero, J. (Javier); Calvo-González, A. (Alfonso); Ruiz-de-los-Mozos, I. (Igor); Barainka, M. (Martin); Zheleva, A. (Angelina); Huesa-Berral, C. (Carlos)